Nothing Special   »   [go: up one dir, main page]

BR112018011319A2 - novos anticorpos anti-claudina e métodos de uso - Google Patents

novos anticorpos anti-claudina e métodos de uso

Info

Publication number
BR112018011319A2
BR112018011319A2 BR112018011319A BR112018011319A BR112018011319A2 BR 112018011319 A2 BR112018011319 A2 BR 112018011319A2 BR 112018011319 A BR112018011319 A BR 112018011319A BR 112018011319 A BR112018011319 A BR 112018011319A BR 112018011319 A2 BR112018011319 A2 BR 112018011319A2
Authority
BR
Brazil
Prior art keywords
methods
new anti
claudin antibodies
antibodies
claudin
Prior art date
Application number
BR112018011319A
Other languages
English (en)
Inventor
A Stull Robert
A Williams Samuel
Fong Sarah
Natwarsinhji Sisodiya Vikram
Original Assignee
Abbvie Stemcentrx Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Stemcentrx Llc filed Critical Abbvie Stemcentrx Llc
Publication of BR112018011319A2 publication Critical patent/BR112018011319A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68035—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a pyrrolobenzodiazepine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

são proporcionados aqui novos anticorpos anti-cldn e conjugados-anticorpo fármaco (adc), incluindo seus derivados, e métodos de uso dos mesmos para tratar distúrbios proliferativos.
BR112018011319A 2015-12-04 2016-12-02 novos anticorpos anti-claudina e métodos de uso BR112018011319A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562263542P 2015-12-04 2015-12-04
US201662427027P 2016-11-28 2016-11-28
PCT/US2016/064617 WO2017096163A1 (en) 2015-12-04 2016-12-02 Novel anti-claudin antibodies and methods of use

Publications (1)

Publication Number Publication Date
BR112018011319A2 true BR112018011319A2 (pt) 2018-12-04

Family

ID=58797837

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018011319A BR112018011319A2 (pt) 2015-12-04 2016-12-02 novos anticorpos anti-claudina e métodos de uso

Country Status (23)

Country Link
US (1) US20190083645A1 (pt)
EP (1) EP3383917A4 (pt)
JP (1) JP2019500335A (pt)
KR (1) KR20180088445A (pt)
CN (1) CN108473588A (pt)
AU (1) AU2016364853A1 (pt)
BR (1) BR112018011319A2 (pt)
CA (1) CA3006738A1 (pt)
CL (2) CL2018001481A1 (pt)
CO (1) CO2018005752A2 (pt)
CR (1) CR20180348A (pt)
DO (1) DOP2018000138A (pt)
EC (1) ECSP18049762A (pt)
HK (1) HK1254743A1 (pt)
IL (1) IL259681A (pt)
MA (1) MA43385A (pt)
MX (1) MX2018006782A (pt)
PE (1) PE20181302A1 (pt)
PH (1) PH12018501153A1 (pt)
RU (1) RU2018124319A (pt)
SG (1) SG11201804673WA (pt)
TW (1) TW201726175A (pt)
WO (1) WO2017096163A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA40921A (fr) * 2014-11-05 2017-09-12 Abbvie Stemcentrx Llc Récepteurs antigéniques chimériques anti-cldn et procédés d'utilisation
ES2979068T3 (es) 2016-07-08 2024-09-24 Crage Medical Co Ltd Anticuerpos para anti-claudina 18A2 y utilización de los mismos
HRP20220311T1 (hr) * 2017-08-18 2022-05-13 Medimmune Limited Konjugati pirolobenzodiazepina
RU2020112280A (ru) * 2017-09-02 2021-10-05 Эббви Инк. Конъюгаты анти-egfr антитело-лекарственное средство (adc) и их применение
CA3073331A1 (en) * 2017-09-02 2019-03-07 Abbvie Inc. Anti-egfr antibody drug conjugates (adc) and uses thereof
CN116999572A (zh) 2017-09-29 2023-11-07 第一三共株式会社 抗体－药物偶联物、药物组合物及其在制备治疗肿瘤的药物中的应用
JP2021525265A (ja) * 2018-05-25 2021-09-24 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン複合体
EP3924389A4 (en) 2019-02-15 2023-06-14 Integral Molecular, Inc. CLAUDIN-6 ANTIBODIES AND THEIR USES
BR112021018608A2 (pt) 2019-03-20 2021-11-23 Univ California Anticorpos para claudina-6 e conjugados de fármaco
US20220168440A1 (en) 2019-03-25 2022-06-02 Daiichi Sankyo Company, Limited Antibody-pyrrolobenzodiazepine deprivative conjugate
EP4054648A4 (en) 2019-11-05 2023-12-27 LaNova Medicines Limited ANTIBODY-DRUG CONJUGATES TARGETING CLAUDINE 18.2
UY39610A (es) 2021-01-20 2022-08-31 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
KR102451185B1 (ko) * 2021-08-05 2022-10-07 환인제약 주식회사 도네페질 함유 지속방출형 미립구
CN114878728A (zh) * 2022-05-06 2022-08-09 浙江大学 一种新型的抗体肽图检测还原方法
WO2024118771A1 (en) 2022-11-30 2024-06-06 Integral Molecular, Inc. Antibodies directed to claudin 6, including bispecific formats thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2425309B (en) * 2003-12-31 2008-07-09 Council Scient Ind Res C2-fluoro pyrrolo[2,1-c][1,4]benzodiazepine dimers
US7189710B2 (en) * 2004-03-30 2007-03-13 Council Of Scientific And Industrial Research C2-fluoro pyrrolo [2,1−c][1,4]benzodiazepine dimers
AU2011239522B2 (en) * 2010-04-15 2014-10-23 Medimmune Limited Targeted pyrrolobenzodiazapine conjugates
PL2839860T3 (pl) * 2012-10-12 2019-10-31 Medimmune Ltd Pirolobenzodiazepiny i ich koniugaty
WO2014075697A1 (en) * 2012-11-13 2014-05-22 Biontech Ag Agents for treatment of claudin expressing cancer diseases
WO2015069794A2 (en) * 2013-11-06 2015-05-14 Stem Centrx, Inc. Novel anti-claudin antibodies and methods of use

Also Published As

Publication number Publication date
PH12018501153A1 (en) 2019-01-28
EP3383917A4 (en) 2019-08-21
ECSP18049762A (es) 2018-07-31
PE20181302A1 (es) 2018-08-09
TW201726175A (zh) 2017-08-01
CL2019000189A1 (es) 2019-06-07
US20190083645A1 (en) 2019-03-21
MX2018006782A (es) 2018-11-09
CN108473588A (zh) 2018-08-31
WO2017096163A1 (en) 2017-06-08
RU2018124319A (ru) 2020-01-09
CA3006738A1 (en) 2017-06-08
AU2016364853A1 (en) 2018-06-21
HK1254743A1 (zh) 2019-07-26
SG11201804673WA (en) 2018-06-28
JP2019500335A (ja) 2019-01-10
MA43385A (fr) 2018-10-10
CL2018001481A1 (es) 2018-08-24
KR20180088445A (ko) 2018-08-03
IL259681A (en) 2018-07-31
CO2018005752A2 (es) 2018-06-12
DOP2018000138A (es) 2018-12-31
EP3383917A1 (en) 2018-10-10
CR20180348A (es) 2018-08-23

Similar Documents

Publication Publication Date Title
BR112018011319A2 (pt) novos anticorpos anti-claudina e métodos de uso
CL2019000334A1 (es) Nuevos conjugados de anticuerpo y usos de los mismos (divisional solicitud 201502357)
BR112016013048A2 (pt) anticorpos anti-dpep3 e métodos de uso
PH12016500781A1 (en) Novel anti-claudin antibodies and methods of use
CL2017002422A1 (es) Derivados de maitansinoide, conjugados de los mismos, y métodos de uso.
CO2018001624A2 (es) Conjugados anticuerpo anti-dll3-fármaco y métodos de uso
CL2018002012A1 (es) Derivados de maitansinoide, conjugados de los mismos y métodos de uso.
CL2018001722A1 (es) Nuevos anticuerpos anti-mfi2 y métodos de uso (divisional solicitud 201700506)
BR112016024525A2 (pt) novos anticorpos anti-rnf43 e métodos de uso
BR112017018940A2 (pt) anticorpos sítio-específicos projetados e métodos de uso
BR112017009517A2 (pt) receptores de antígeno quimérico anti-cldn e métodos de uso
BR112016004245A2 (pt) moduladores de sez6 e métodos de uso
BR112018010279A2 (pt) novos anticorpos anti-emr2 e métodos de uso
BR112016016870A2 (pt) Derivados de icariina, seus usos, e composição farmacêutica
CL2017002680A1 (es) Construcciones de calicheamicina y sus métodos de uso
BR112018012884A2 (pt) novos anticorpos anti-mmp16 e métodos de uso
BR112018012883A2 (pt) novos anticorpos anti-upk1b e métodos de uso
BR112018070603A2 (pt) formulações líquidas de fosfaplatina

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]